Molecular epidemiology of lung cancer

肺癌的分子流行病学

• 批准号: 7147646
• 负责人: Anil Vachani
• 金额: $ 13.84万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-09 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7147646
• 关键词: clinical research; epidemiology; genes; lung; neoplasm /cancer

DESCRIPTION (provided by applicant): Anil Vachani, M.D. is a member of the Pulmonary, Allergy, and Critical Care Division at the University of Pennsylvania School of Medicine and is a faculty-fellow in the Department of Biostatistics and Epidemiology. The career development component of the award proposed herein includes a preceptorship with Dr. Timothy Rebbeck, Director of Cancer Epidemology at Penn, and advanced coursework in molecular epidemiology. Additional training will be obtained in laboratory techniques necessary for the conduct of well designed molecular epidemiologic studies. This program of didactic and applied instruction will extend Dr. Vachani's training, will be directly applicable to timely completion of his research proposal, and will provide him with the necessary foundation to become an independent investigator in the molecular epidemiology of lung cancer. The goal of the proposed research is to evaluate the role of candidate genetic polymorphisms in the determination of outcomes among patients with lung cancer. Lung cancer is the most common worldwide cause of major cancer incidence and mortality. At present, the ability to predict outcome in patients with surgically resected tumors is limited. Although surgical therapy may be curative, a number of variables including mechanisms related to the immune system may influence the risk of recurrence and survival in patients with resected lung cancer. The hypothesis underlying Dr. Vachani's project is that higher levels of immune tolerance and escape play a key role in the outcome of NSCLC. More specifically, we will test the association of genetic variation in immunosuppressive genes with tumor characteristics and outcomes in patients with NSCLC. Gene-gene interactions and higher order interactions will also be evaluated. Results from this project may provide valuable insight into immune mechanisms involved in lung cancer progression and allow for the identification of patients that may benefit from adjuvant therapy, particularly novel immunotherapeutic strategies.

描述（由申请人提供）：Anil Vachani 医学博士是宾夕法尼亚大学医学院肺科、过敏科和重症监护科的成员，也是生物统计和流行病学系的教员。本文提出的奖项的职业发展部分包括宾夕法尼亚大学癌症流行病学主任 Timothy Rebbeck 博士的指导，以及分子流行病学的高级课程。将获得进行精心设计的分子流行病学研究所需的实验室技术方面的额外培训。这一教学和应用指导计划将扩展 Vachani 博士的培训，将直接适用于他的研究计划的及时完成，并将为他成为肺癌分子流行病学的独立研究者提供必要的基础。拟议研究的目的是评估候选基因多态性在确定肺癌患者预后中的作用。肺癌是全球主要癌症发病率和死亡率的最常见原因。目前，预测手术切除肿瘤患者的结果的能力有限。尽管手术治疗可能有效，但包括免疫系统相关机制在内的许多变量可能会影响已切除肺癌患者的复发和生存风险。 Vachani 博士项目的假设是，较高水平的免疫耐受和逃逸在 NSCLC 的预后中发挥着关键作用。更具体地说，我们将测试免疫抑制基因的遗传变异与 NSCLC 患者的肿瘤特征和结果的关联。基因-基因相互作用和高阶相互作用也将被评估。该项目的结果可能为肺癌进展中涉及的免疫机制提供有价值的见解，并允许识别可能受益于辅助治疗，特别是新型免疫治疗策略的患者。